Skip to main content

Tweets

To Pulse or Not to Pulse in ANCA Associated Vasculitis? New #ACR26 data found no significant remission benefit with pulse steroids, but serious infections were higher (31% vs 14%). Is it time to rethink their use? Dr. Michael Putman weighs in: https://t.co/b6cJkI2aXc https://t.co/rM3eoRBJYW
Dr. John Cush @RheumNow ( View Tweet )
1 hour 31 minutes ago
What does CAR-T safety look like between autoimmune disease and heme-onc? Here's CRS and ICANS within the cohorts so far (although don't forget about the lymphodepletion) Anca Askanase @HSpecialSurgery #ACR26 @RheumNow https://t.co/GkDGDiOET4
David Liew @drdavidliew ( View Tweet )
2 hours 24 minutes ago
Two Prescriptions, One Patient Obesity, in particular in PsA was widely covered at #ACR26. In the Swiss SCQM registry, 63.6% of 2,087 patients with PsA were overweight or obese, compared with 31% overweight and 12% obese in the Swiss population, and higher BMI tracked disease https://t.co/Ys5wTvQ2r9
Dr. John Cush @RheumNow ( View Tweet )
2 hours 30 minutes ago
ACR 2026 Day 4 Report The last day of ACR 2026 was a half-day but a busy day, with several exciting reports, especially coming from the late-breaking abstracts. https://t.co/wBfrQhwZHy https://t.co/plZgG0Y7VN
Dr. John Cush @RheumNow ( View Tweet )
3 hours 30 minutes ago
ACR 2026: RA Topic Panel https://t.co/4Jttct8XKe

Dr. John Cush @RheumNow ( View Tweet )

3 hours 31 minutes ago
TRBV9+ a novel treatment approach for AxSpA? https://t.co/sNV9KsgvNa https://t.co/b6fRnwdLYf
Dr. John Cush @RheumNow ( View Tweet )
4 hours 1 minute ago
Check the genetics in your patients with ILD A common misconception is that genetic variants don’t cause disease in adults, says Dr. Korf. According to Dr. Bogunovic, 1 in 4 adults will have a first manifestation of genetic error of immunity in adulthood. Genetics seems to be https://t.co/qRUV0oiu0a
Dr. John Cush @RheumNow ( View Tweet )
5 hours 30 minutes ago
T-Cell Engagers in Autoimmunity: CRS From 12% to 67% Across Six Reports Six ACR 2026 reports put BCMA, CD19, CD20 and gamma-delta engagers side by side in autoimmune disease. The efficacy signal is consistent. The safety signal depends almost entirely on how the molecule was https://t.co/PHm1fF3Tg4
Dr. John Cush @RheumNow ( View Tweet )
6 hours 16 minutes ago
Cardiovascular Risk in Axial Spondyloarthritis When a patient with axial spondyloarthritis patient sits in your clinic, their joint inflammation is only half the story. To truly achieve disease control, one should ask: “Am I consistently and aggressively screening them all for https://t.co/t0hLcKIowz
Dr. John Cush @RheumNow ( View Tweet )
7 hours 30 minutes ago
CAR T Gets the Spotlight. Are We Missing the B Cells That Matter? CAR T is having its moment in rheumatology. But William Robinson’s presentation at ACR Convergence 2026 raised a question I find even more compelling: are we failing to eliminate the right B cells with therapies https://t.co/uta77oaayo
Dr. John Cush @RheumNow ( View Tweet )
8 hours 30 minutes ago
Falls Hide in Plain Sight in Rheumatic Disease A patient with arthritis pitches forward onto her knees and wrists while bending to grab something. Another time she tries to get up and lands on the bed. Another time she uses a chair to lower herself to the floor. By the World https://t.co/kmmaRxhII0
Dr. John Cush @RheumNow ( View Tweet )
9 hours 30 minutes ago
Is It Still Inflammation? A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation? https://t.co/fLGgnBCXS8
Dr. John Cush @RheumNow ( View Tweet )
11 hours 1 minute ago
Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA 14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA https://t.co/tErmfDBy1r
Dr. John Cush @RheumNow ( View Tweet )
14 hours ago
IgG4-RD in 3 Talks: Shorter Steroids, Earlier B-Cell Therapy IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point. https://t.co/pWu1eoiMVG https://t.co/k9aFvYhQSB
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/EkudaG7YiY
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
×